Alpha Tau Reports Positive Interim GBM Data with 100% ORR and Median Survival Not Reached; Stock Likely to Re-rate on Strengthened Clinical Proof

What happened

Alpha Tau announced positive interim results from its U.S. recurrent glioblastoma trial, with all eight treated patients alive as of November 11, 2026, and median overall survival not yet reached. In the first six evaluable patients with a median follow-up of 6.9 months, the objective response rate (ORR) was 100%, and all treatments were feasible with no unanticipated serious adverse events. This update extends earlier safety data from the first three patients reported in Q2 2026, and it comes ahead of management's prior guidance for GBM recruitment completion in second half 2026. The positive efficacy signal, though based on a small sample, bolsters confidence in Alpha DaRT's potential for hard-to-treat brain cancers and aligns with the company's strategy to generate U.S. clinical momentum. The market has yet to fully digest the news; prior to this, the stock was rated WAIT at $7.25 with a base-case implied value of $7.75 and a bull case of $9.50, and this data could shift the risk-reward skew upward.

Implication

The 100% ORR and absence of serious adverse events in six evaluable patients is a meaningful early signal, but the sample is small and follow-up short; the 20-F cautions that interim results can change materially. This data reduces the clinical risk premium for the GBM program and may accelerate partnership discussions, but it does not address the core commercialization question: whether Japan PMS enrollment progresses and reimbursement path with MHLW materializes. If subsequent GBM data at longer follow-up maintains efficacy and safety, the bull scenario ($9.50) becomes more likely, and the company's valuation could re-rate toward the higher end of the scenario range. However, the stock has already rallied from $2.60 to $7.25 over the past year, and the current price may already embed some GBM success; investors should be disciplined and avoid chasing strength without additional confirmation. The re-assessment window should focus on Japan PMS activation and enrollment, as well as final GBM data; a positive Japan update combined with sustained GBM efficacy could justify moving from WAIT to BUY, while any deterioration would cap upside.

Thesis delta

The previous WAIT thesis hinged on time-boxed proof points, including the Q2 2026 GBM safety readout. The new interim GBM results deliver a positive signal with 100% ORR and all patients alive, reducing clinical risk but not eliminating it given small sample and interim nature. The thesis shifts from 'wait for safety readout' to 'wait for durability and Japan commercial traction,' with an increased probability of the bull scenario.